UroGen Pharma Ltd (URGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
UroGen Pharma Ltd stock (URGN) is currently trading at $18.12. UroGen Pharma Ltd PS ratio (Price-to-Sales) is 7.81. Analyst consensus price target for URGN is $35.62. WallStSmart rates URGN as Sell.
- URGN PE ratio analysis and historical PE chart
- URGN PS ratio (Price-to-Sales) history and trend
- URGN intrinsic value — DCF, Graham Number, EPV models
- URGN stock price prediction 2025 2026 2027 2028 2029 2030
- URGN fair value vs current price
- URGN insider transactions and insider buying
- Is URGN undervalued or overvalued?
- UroGen Pharma Ltd financial analysis — revenue, earnings, cash flow
- URGN Piotroski F-Score and Altman Z-Score
- URGN analyst price target and Smart Rating
UroGen Pharma
📊 No data available
Try selecting a different time range
Smart Analysis
UroGen Pharma Ltd (URGN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
UroGen Pharma Ltd (URGN) Key Strengths (2)
Revenue surging 54.00% year-over-year
97.84% of shares held by major funds and institutions
Supporting Valuation Data
UroGen Pharma Ltd (URGN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 19.3x book value
Premium valuation at 7.8x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
UroGen Pharma Ltd (URGN) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 54.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (7.81), Price/Book (19.27) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1481.00%, Operating Margin at -50.50%, Profit Margin at -139.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1481.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 54.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
URGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
URGN's Price-to-Sales ratio of 7.81x trades at a deep discount to its historical average of 218.4x (23th percentile). The current valuation is 100% below its historical high of 1763.63x set in Jan 2019, and 255% above its historical low of 2.2x in May 2025. Over the past 12 months, the PS ratio has expanded from ~5.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for UroGen Pharma Ltd (URGN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
UroGen Pharma Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 110M with 54% growth year-over-year. The company is currently unprofitable, posting a -139.8% profit margin.
Key Findings
Revenue growing at 54% YoY, reaching 110M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -1.13 indicates a conservative balance sheet with 90M in cash.
The company is unprofitable with a -139.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -38M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can UroGen Pharma Ltd maintain 54%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact UroGen Pharma Ltd.
Bottom Line
UroGen Pharma Ltd is a high-conviction growth story with revenue accelerating at 54% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -139.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About UroGen Pharma Ltd(URGN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
UroGen Pharma Ltd (URGN) is a biotechnology company focused on pioneering therapies for urological conditions, particularly urothelial carcinoma and bladder cancer. Utilizing its proprietary reverse thermal gel platform, UroGen facilitates sustained local drug delivery, enhancing therapeutic effectiveness while minimizing systemic exposure. The company boasts a robust clinical pipeline aimed at addressing critical unmet needs within urology, positioning itself as a leader in the sector with the potential to significantly improve patient outcomes.